Comparison of Weight Loss and Nutritional Deficiency After One Anastomosis Gastric Bypass at 150, 170, and 200 cm From the Duodenojejunal Junction
NCT06664099
Bariatric Surgery (Gastric Bypass), Body Weight
Cairo, Egypt
View Trial DetailsNCT Number: NCT07252765
The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk of it, and who are prescribed a diabetes-specific oral nutritional supplement (ONS) that is high in calories and protein and contains soluble fiber.
Participants will complete a series of questionnaires during visits 1 and 3.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
To assess changes in glycemic and metabolic control.
To evaluate the nutritional and functional impact of the ONS.
To analyze healthcare resource utilization and associated costs.
To estimate patient adherence, compliance, and satisfaction with the prescribed ONS.
To assess quality-of-life outcomes over a 6-month follow-up period.
Multicenter, prospective, real-world evidence (RWE) study.
Conducted across 12 hospitals in Spain.
Three scheduled visits: baseline (V1), 3-month follow-up (V2), and 6-month final visit (V3).
Sociodemographic: age, sex, education level, etc.
Clinical and anthropometric: weight, muscle mass, comorbidities.
ONS-related: product name, dosage, duration, modifications, palatability.
Nutritional requirements: daily caloric, protein, fat, and carbohydrate needs.
Healthcare resource utilization: hospital admissions, emergency visits, specialist consultations, and diabetes medication adjustments.
Metabolic profile: HbA1c, fasting glucose, lipid panel, albumin, total protein, hemoglobin, liver enzymes, eGFR, and CRP.
Functional assessment: SARC-F scale, handgrip strength, bioelectrical impedance analysis (BIA), nutritional ultrasound, and Timed Up and Go test.
Patient-reported outcomes: NutriQoL® quality-of-life questionnaire, satisfaction survey, treatment adherence questionnaire, and ONS palatability scale.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline visit (V1)
Descriptive information of the population at V1
Time frame: From enrollment to end of treatment at 24 weeks
Changes in blood test measures will be compared
Time frame: From enrollment to end of treatment at 24 weeks
Changes in GLIM or MUST classifications
Time frame: From enrollment to end of treatment at 24 weeks
They will be estimated by multiplying the number of units used by their unit cost (derived from eSalud and Botplus databases). Unit: Number of events; euros (€)
Time frame: From enrollment to end of treatment at 24 weeks
Participants will be categorized as compliant (≥80% consumption) or non-compliant (<80%).
Time frame: From enrollment to end of treatment at 24 weeks
Changes between visits in SARC-F scale categories
Time frame: From enrollment to end of treatment at 24 weeks
Patients will be classified according to a quality-of-life category (excellent, good, acceptable, poor, very poor). Test total scoring values.
Time frame: From enrollment to end of treatment at 24 weeks
Responses to the satisfaction questionnaires will be summarized as number and percentage of participants selecting each category at V3.
Time frame: From enrollment to end of treatment at 24 weeks
Responses to the palatability questionnaires will be summarized as number and percentage of participants selecting each category at V3.
Time frame: From enrollment to end of treatment at 24 weeks
Frequencies of treatment changes, administration route, specialist consultations, and hospitalizations will be recorded and quantitative variables (treatment dose, treatment duration, number and days of hospitalization, consultations) will be summarized using mean ± SD.
Time frame: From enrollment to end of treatment at 24 weeks
It will be estimated according to GLIM or MUST classification
Time frame: From enrollment to end of treatment at 24 weeks
Weight and height will be combined to report BMI in kg/m2
Time frame: From enrollment to end of treatment at 24 weeks
Probe: handgrip test by using a hand dynamometer
Time frame: From enrollment to end of treatment at 24 weeks
Test: a patient will have to stand-up and sit-down as maximim number of times in 30", from a chair, with both arms crossed in the chest.
Time frame: From enrollment to end of treatment at 24 weeks
Test: bioimpedance
Time frame: From enrollment to end of treatment at 24 weeks
Test: nutritional (morphofunctional) ecography
Contact information is provided by the study sponsor or research team.
Outcomes'10
Network
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice. STARLIGHT Study
Acronym: STARLIGHT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06664099
Bariatric Surgery (Gastric Bypass), Body Weight
Cairo, Egypt
View Trial DetailsNCT07463209
Autoimmune Diseases, Diabetes (DM)
Chapel Hill, North Carolina, United States
View Trial DetailsNCT07728669
Body Weight, Diabetes Mellitus
Almaty, Kazakhstan
View Trial DetailsNCT06836479
Diabetes Mellitus, Diabetes Mellitus, Type 2
Stanford, California, United States
View Trial Details